IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by AlphaQuest LLC

AlphaQuest LLC trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 77.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,661 shares of the company’s stock after selling 26,401 shares during the quarter. AlphaQuest LLC’s holdings in IDEAYA Biosciences were worth $197,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. FMR LLC raised its stake in shares of IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after buying an additional 1,365,570 shares during the period. Janus Henderson Group PLC raised its stake in IDEAYA Biosciences by 26.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. State Street Corp raised its stake in IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Geode Capital Management LLC raised its stake in IDEAYA Biosciences by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock valued at $61,645,000 after purchasing an additional 172,838 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in IDEAYA Biosciences in the 3rd quarter valued at $42,681,000. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDYA has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.58.

IDEAYA Biosciences Trading Down 2.0 %

NASDAQ IDYA opened at $18.58 on Monday. The stock has a market cap of $1.63 billion, a PE ratio of -5.63 and a beta of 0.76. IDEAYA Biosciences, Inc. has a twelve month low of $16.95 and a twelve month high of $46.40. The stock has a fifty day simple moving average of $21.95 and a 200-day simple moving average of $27.15.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. Research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.